干扰素-α2b抗肿瘤作用临床Ⅱ期观察

Antitumor effects of interferon a2b in phase Ⅱ clinical trials

自80年代初基因重组干扰素(IFN)问世以来,IFN的抗肿瘤作用的研究有了很大的进展。特别是IFN-α2b的临床研究较为深入。目前已知IFN-α2b对毛细胞白血病、慢性髓性白血病、肾癌,非何杰金淋巴瘤、恶性黑色素瘤等有肯定的疗效。IFN对其它肿瘤的疗效也正在研究中。近年来,我院用美国Schering公司提供的IFN-α2b(Intron A)治疗27例晚期肿瘤病人,现将初步临床观察结果报告如下。临床资料及给药方法 1986年5月～1989年3月共收治经病理证实的晚期肿瘤病人27例。

The results of 27 cases of advanced malignancies treated with interferon a2b (Intron A) are presented. The drug was given 3×10~6 IU intramuscularly twice in the first week, 5×10~6 IU twice in the second week, and then 10×10~6 IU twice for 4 weeks. Among 23 evaluable cases, 2/11 of malignant melanoma and 1/1 of breast cancer reached partial response after treatment) while no effect was observed in 9 cases of renal cell carcinoma, one case of multiple myeloma and one case of Hodgkin's disease. Main side effects were flu-like fever and mild bone marrow depression. The role of interferon in the management of malignant disease is also discussed.